Form PTO-1449

IN AN APPLICATION

(Use several sheets if necessary)

	Sheet 1 01 6
Docket Number 399632001920	Application Number 09/189,702
Applicant	
Alessan	ndro SETTE, et al.
Filing Date November 10, 1998	Group Art Unit 1644
Mailing Date July 5, 2002	

U.S. PATENT DOCUMENTS

		,					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/1986	4,599,230	Milich et al.	424	189.1	
	2.	07/1991	5,028,425	Good et al.	424	191.1	
·.	3.	08/1994	5,342,774	Boon et al.	435	371	,
	4.	04/1993	5,200,320	Sette et al.	435	7.24	
	5.	04/1995	5,405,940	Boon et al.	530	328	
	6.	10/1995	5,462,871	Boon-Falleur et al.	435	354	
	7.	04/1996	5,503,829	Ladant et al.	424	192.1	
	8.	09/1997	5,662,907	Kubo et al.	424	185.1	
	9.	04/1998	5,736,142	Sette et al.	424	185.1	
	10.	05/1998	5,750,395	Fikes et al.	435	325	
	11.	11/1998	5,840,303	Chisari et al.	424	152.1	
	12.	03/2000	6,037,135	Kubo et al.	435	7.24	
	13.	05/2000	6,063,900	Melief et al.	530	327	
	14.	06/2000	6,075,122	Cheever et al.	530	350	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Trans YES	slation NO
	15.	01/1982	EP 44710	Europe				
	16.	06/1987	EP 0226513	Europe			1	
	17.	06/1989	EP 0346022	Europe				
	18.	08/1996	EP 0534615	Europe				
	19.	08/1996	EP 0728764	Europe				
	20.	02/1992	WO 92/02543	WIPO				
	21.	08/1992	WO92/12996	WIPO				
	22.	11/1992	WO 92/21033	WIPO				

EXAMINER: DATE CONSIDERED:

FEB 2 2 700 EST

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632001920 Application Number 09/189,702

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

23.	03/1993	WO 93/03753	WIPO		-
24.	. 03/1993	WO 93/03764	WIPO		1
25.	09/1993	WO 93/17095	WIPO		
 26.	11/1993	WO 93/22338	WIPO		
27.	02/1994	WO 94/03205	WIPO		
28.	03/1994	WO94/05304	WIPO		T
29.	05/1994	WO 94/11738	WIPO		
 30.	04/1995	WO 95/11255	WIPO		T
31.	08/1995	WO 95/23234	WIPO	_	
32.	02/1997	WO 97/04802	WIPO		
 33.	08/1997	WO 97/29195	WIPO		

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title	
	34.	Alexander et al. "Generation of Tumor-specific Cytolytic T Lymphocytes from Peripheral Blood of Cervical Cancer Patients by In Vitro Stimulation with a Synthetic Human Papillomavirus Type 16 E7 Epitope" Am. J. Obstet. Gynecol. 175:1586-1593 (1996)	
	35.	Alexander et al., J. Immunol. (1997) 159:4753-4761	
	36.	Altfeld et al., J. Virol. (2001) 75:1301-1311	
	37.	Benjamin et al., Nature (1991) 351:74-77	
	38.	Bergmann et al., J. Virol. (1994) 68:5306-5310	
	39.	Bertoni et al., J. Clin. Invest. (1997) 100:503-513	
	40.	Bjorkman et al. "Structure of the Human Class I Histocompatibility Antigen HLA-A2" Nature 329:506 (1987)	
	41.	Boel et al., Immunity (1995) 2:167	
	42.	Boon. Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy" Int. J. Cancer 54:177-180 (1993)	
	43.	Bosisio et al., Gazz. Chim. Ital. (1967) 97(12):1848-1857	
	44.	Bruss. "A Short Linear Sequence in the Pre-S Domain of the Large Hepatitis B Virus Envelope Protein Required from Virion Formation" J. Virology 71(12):9350-9357 (1997)	
	45.	Buus et al. "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia" Science 242:1045-1047 (1988)	

EXAMINER:

DATE CONSIDERED:

PTO/SB/08 (2-92) Sheet 3 of 8 Docket Number 399632001920 Application Number 09/189,702 Form PTO-1449 INFORMATION DISCLOSUPE CITATION Applicant Alessandro SETTE, et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date November 10, 1998 Group Art Unit 1644 Mailing Date July 5, 2002 46. Carreno et al. "HLA-B37 and HLA-A2.1 Molecules Bind Largely Nonoverlapping Sets of Peptides" Proc. Natl. Acad. Sci. USA 87:3420-3424 (1990) Castellanos et al., Gynecologic Oncology (2001) 82:77-83 47. 48. Castellanos et al., Oncology/Hematology (2001) 39:133-138 49. Celis et al. "Identification of Potential CTL Epitopes of Tumor Associated Antigen MAGE-1 for Five Common HLA-A Alleles" Molec. Immunol. 3:1423-1430 (1994) 50. Celis et al. "Epitope Selection and Development of Peptide Based Vaccines to Treat Cancer" Cancer Biology 6:329-336 (1995) Chang et al., J. Immunol. (1999) 162:1156-1164 51. 52. Chen and Parham, Nature (1989) 337:743-745 Cotran et al. (ed.) Robbins Pathologic Basis of Disease, 4th ed., W.B. Saunders Co., Philadelphia pp. 53. 296-299 (1989) 54. Culmann et al., (1991) 146(5):1560-1565 55. De Bruijn et al. "Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses" Eur. J. Immunol. 21:2963-2970 (1991) 56. Del Val et al., Cell (1991) 66:1145-1153 57. DiBrino et al. "Endogenous Peptides Bound to HLA-A3 Possess a Specific Combination of Anchor Residues That Permit Identification of Potential Antigenic Peptides" Proc. Nat'l. Acad. Sci. USA 90:1508-1512 (1993) Dibrino et al., J. Immunol. (1993) 151:5930-5935 58. 59. Diepolder et al., J. Virol. (1997) 71(8):6011-6019 Ding et al. "Cloning and Analysis of MAGE-1-Related Genes" Biochem. Biophys. Res. Commun. 60. 202(1):549-555 (1994) Ding et al., Immunity (1998) 8:403-411 61. 62. Doolan et al., Immunity (1997) 7:97-112 63. Doolan et al., J. Immunol. (2000) 165:1123-1137 64. Edgington. "How Sweet It Is: Selectin-Mediating Drugs" Biotechnology 10:383-389 (1992) 65. Eisenlohr et al., J. Exp. Med. (1992) 175:481-487 Engelhard et al. "Structure of Peptides Associated with MHC Class I Molecules" Curr. Opin. 66. Immunol. 6:13-23 (1994) Falk et al., J. Exp. Med. (1991) 174:425-434 67.

EXAMINER:

68.

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Molecules" Nature 351:290-296 (1991)

Falk et al. "Allele-specific Motifs Revealed by Sequencing of Self-peptide Eluted from MHC

PTO/SB/08 (2-92) Sheet 4 of 8

Form PTO-1449
INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

	Direct 4 of 0
Docket Number 399632001920	Application Number 09/189,702
Applicant	
Alessan	dro SETTE, et al.
Filing Date November 10, 1998	Group Art Unit 1644
Mailing Data July 5 2002	

		Mailing Date July 5, 2002		
	69.	Feltkamp et al. "Vaccination with Cytotoxic T Lymphocyte Epitope-containing Peptide Protects Against a Tumor Induced by Human Papillomavirus Type 16-transformed Cells" Eur. J. Immunol. 23:2242-2249 (1993)		
	70.	Foon. "Biological Response Modifiers: the New Immunotherapy" Cancer Res. 49:1621-1639 (1989)		
	71.	Fynan et al. "DNA Vaccines: Protective Immunizations by Parental, Mucosal, and Gene-gun Inoculations" Proc. Nat'l. Acad. Sci. USA 90:11478-11482 (1993)		
	72.	Gambacorti-Passerini et al., Clin. Cancer Res. (1997) 3:675-683		
	73.	Gaugler et al. "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes" J. Exp. Med. 179(3):921-930 (1994)		
	74.	Gavioli et al., Proc. Natl. Acad. Sci. USA (1992) 89:5862-5866		
	75.	Gonzalez et al., Parasite Immunology (2000) 22:501-514		
	76.	Guo et al., Nature (1992) 360:364-366		
	77.	Hayashi et al. "Molecular Cloning and Characterization of the Gene Encoding Mouse Melanoma Antigen by cDNA Library Transfection" J. Immunol. 149:1223-1229 (1992)		
	78.	Henderson et al. "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation" Science 255:1264-1266 (1992)		
	79.	Hill et al., Nature (1992) 360:434-439		
	80.	Huczko et al., J. Immunol. (1993) 151:2572-2587		
	81.	Hunt et al. "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry" Science 255:1261-1263 (1992)		
	82.	Hurtenbach et al. "Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice by Treatment with a Class II Major Histocompatibility Complex-blocking Peptide" J. Exp. Med. 177:1494-1504 (1993)		
	83.	Ishioka et al., J. Immunol. (1999) 162:3915-3925		
	84.	Jameson and Bevan, Eur. J. Immunol. (1992) 22:2663-2667		
	85.	Jardetzky et al. "Identification of Self Peptides Bound to Purified HLA-B27" Nature 353:326-329 (1991)		
	86.	Jiang et al. "Role of CD8* T Cells in Murine Experimental Allergic Encephalomyelitis" Science 256:1213-1215 (1992)		
	87.	Kannagi et al. "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cytotoxic T Cells" J. of Virol. 66(5):2928-2933 (1992)		
	88.	Karin et al J. Exp. Med. 180:2227-2237 (1994)		
	89.	Kast et al., J. Immunol. (1994) 152:3904-3912		
EXAMD	NED.	DATE CONSIDERED		

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 Docket Number 399632001920 Application Number 09/189,702 INFORMATION DISCLOSURE Applicant Alessandro SETTE, et al. IN AN APPLICATION FEB 2 2 2005 (Use several sheets if necessary) Filing Date November 10, 1998 Group Art Unit 1644 Mailing Date July 5 . 2002 Kast et al., Eur. J. Immunol. (1993) 23:1189-1192 90. 91. Kawakami et al., J. Immunol. (1995) 154:3961-3968 92. Kawashima et al., "The Multi-Epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors" Human Immunol. (1998) 59:1-14 93. Knuth et al. "Cellular and Humoral Immune Responses Against Cancer: Implication for Cancer Vaccines" Curr. Opinion Immunol. 3:659-664 (1991) 94. Koh et al. "Less Mortality but More Relapses in Experimental Allergic Encephalomyelitis in CDB-Mice" Science 256:1210-1213 (1992) Kozlowski et al., J. Exp. Med. (1992) 175:1417-1422 95. 96. Krieger et al. "Single Amino Acid Changes in DR and Antigen Define Residues Critical for Peptide-MHC Binding and T Cell Recognition" J. Immunol. 146:2331-2340 (1991) 97. Lamonica et al., Hepatology (1999) 30:1088-1098 98. Lehniger. "Principles of Biochemistry" Worth Publishers, Inc. NY; pp. 100-101 (1982) 99. Lipford et al., J. Immunol. (1993) 150:1212-1222 Lustgarten et al., "Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice 100. Expressing HLA-A2.1 and Human CD.8" Human Immunology (1997) 52:109-118 101. Maier et al., (1994) 40:306-308 102. Maryanski et al. "Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers" Cell 60:63-72 (1990) 103. Melief et al. "T-Cell Immunotherapy of Cancer" Res. Immunol. 142:425-429 (1991) 104. Melief et al., Cancer Surveys (1992) 13:81-99 105. Miller et al. "Suppressor T Cells Generated by Oral Tolerization to Myelin Basic Protein to Suppress Both In Vitro and In Vivo Immune Responses by the Release of Transforming Growth Factor β After Antigen-specific Triggering" Proc. Nat'l. Acad. Sci. USA 89:421-425 (1992) 106. Morrison et al. "Identification of the Nonamer Peptide from Influenza A Matrix Protein and the Role of Posckets of HLA-A2 in Its Recognition by Cytotoxic T Lymphocytes" Eur. J. Immunol. 22:903-907 (1992) 107. Niedermann et al., Immunol. Rev. (1999) 172:29-48 108. Niedermann et al., Proc. Natl. Acad. Sci. USA (1996) 93:8572-8577 109. Oaks et al. "Molecular Cytogenetic Mapping of the Human Melanoma Antigen (MAGE) Gene Family to Chromosome Region Xq27-qtr: Implications for MAGE Immunotherapy" Cancer Res. 54:1627-1629 (1994) Ochoa-Garay et al. Molecular Immunology 34:273-281 (1997) 110. DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

2 2 2005

Form PTO-1449	71° v.	Docket Number 399632001920	Application Number 09/189,702			
	ION DISCLOSURE CITATIONS	Applicant Alessandro SETTE, et al.				
<u> </u>	/se several sheets if necessary F. 2 2 2005	Filing Date November 10, 1998	Group Art Unit 1644			
	Mailing Date July <u>5</u> , 2002					
	RADENA					
111.	Pamer et al. "Precise Prediction of a D Monocytogenes" Nature 353:852-855		Epitope of Listeria			
112.	Parker et al. "Peptide Binding to HLA-A2 and HLA-B27 Isolated from Escherichia coli" J. Biol. Chem. 267(8):5451-5459 (1992)					
113.	Parker et al. "Sequence Motifs Importa HLA-A2" J. Immunol. 149:3580-3587		ıman MHC Class I Molecule,			
114.	Parker et al. "Scheme for Ranking Pote Binding of Individual Peptide Side-Ch					
115.	Paul (ed.), Fundamental Immunology,	2 nd ed., Raven Press, NY, pp. 47	73-487 (1989)			
116.	Paul (ed.), Fundamental Immunology,	3 rd ed., Raven Press, NY, pp. 97	6-978 (1993)			
117.	Preisler-Adams et al. "Complete Nucle Identification of Three Types of C Ope					
118.	Prezzi et al., Eur. J. Immunol. (2001) 3	1:894-906				
119.	Rammensee et al. "Peptides Naturally 11:213-244 (1993)	Rammensee et al. "Peptides Naturally Presented by MHC Class I Molecules" Annu. Rev. Immunol. 11:213-244 (1993)				
120.	Rammensee et al. "MHC Ligands and (1995)	Rammensee et al. "MHC Ligands and Peptide Motifs: First Listing" Immunogenetics 41(4):178-228				
121.	Rammensee et al. "SYFPEITHI: Datab 50(3-4):213-219 (1999)	pase for MHC Ligands and Pepti	de Motifs" Immunogenetics			
122.	Rehermann et al., J. Clin. Invest. (1996	5) 97:1655-1665				
123.	Ressing et al. "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides J. Immunol. 154:5934 (1995)					
124.	Rickinson. "Immune Intervention Again 6(Supp. 1): 69-71 (1995)	inst Virus-associated Human Ca	ncers" Annals of Oncology			
125.	Rivoltini et al., J. Immunol. (1995) 154	1:2257-2265	·			
126.	Romero et al. "H-2Kd-restricted Antig 174:603-612 (1991)	enic Peptides Share a Simple Bi	nding Motif" J. Exp. Med.			
127.	Rothbard, Current Opinion in Immuno	logy (1989) 2:99-105				
128.	Rotzschke et al. "Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y" 249:283-287 (1990)					
129.	Rotzschke et al. "Isolation and Analysis of Naturally Processed Viral Peptides As Recognized by Cytotoxic T Cells" Nature 348:252-254 (1990)					
130.	Rotzschke et al. "Naturally Occurring Peptide Antigens Derived from the MHC Class-I-restricted Processing Pathway" Immunology Today 12(12):447-455(1991)					
EXAMINER:		DATE CONSIDERED:				
	al if citation considered, whether or not the citation ot considered. Include a copy of this form with no		ne through the citation if not in			

PTO/SB/08 (2-92) Sheet 7 of 8

FEB 2 2 2005

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ket Number 399632001920

Application Number 09/189,702

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

	(Use several sheets if necessary)	Filing Date November 10, 1998	Group Art Unit 1644	
		Mailing Date July <u>\$</u> , 2002		
131.	Rotzschke et al. "Peptide Motifs of Closely Related HLA Class I Molecules Encompass Substantial Differences" Eur J. Immunol. 22:2453-2456 (1992)			
132.	Rudinger. "Characteristics of the Amino Acids As Components of a Peptide Hormone Sequence" in Peptide Hormones, Parsons (ed.), University Park Press, pp. 1-7 (1976)			
133.	Ruppert et al. "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules" Cell 74(5):929-937 (1993)			
134.		Sarobe et al. "Induction of Antibodies Against a Peptide Hapten Does Not Require Covalent Linkage Between the Hapten and a Class II Presentable T Helper Peptide" Eur. J. Immunol. 21:1555-1558		
135.	Schaeffer et al. Proc. Natl. Acad. Sci. I	JSA 86:4649 (1989)		
136.	Scognamiglio et al., J. Immunol. (1999	9) 162:6681-6689		
137.	Sette et al. "Prediction of Major Histor Analysis" Proc. Nat'l. Acad. Sci. USA	compatibility Complex Binding 86:3296-3300 (1989)	Regions by Sequence Pattern	
138.		Sette et al. "Random Association between the Peptide Repertoire of A2.1 Class I and Several Different DR Class II Molecules" J. Immunol. 147:3893-3900 (1991)		
139.	Sette et al., J. Immunol. (1994) 153:55	86-5592		
140.	Sette and Sidney, Curr. Opin. Immuno	1. (1998) 10:478-482		
141.	Sette et al., in Persistent Viral Infection	ns, Ahmed and Chen (Eds.), John	n Wiley & Sons (1999)	
. 142.	Sette et al., Immunodominance and Bro	eadth of Cellular Responses (20	01) In Press	
143.	Shanker et al. "Three Regions of HIV- (Abstracr) Immunology Letters 52(1):2	Shanker et al. "Three Regions of HIV-1 gp160 Contain Clusters of Immunodominant CTL Epitope (Abstracr) Immunology Letters 52(1):23-30 (1996)		
144.	Shastri et al., J. Immunol. (1995) 155:4	1339-4346		
145.	Sherman et al., J. Exp. Med. (1992) 17	5:1221-1226		
146.	Shimojo et al. "Specificity of Peptide E 143(9):2939-2947 (1989)	Binding by the HLA-A2.1 Molec	cule" J. of Immunol.	
147.		Slingluff et al. "Recognition of Human Melanoma Cells by HLA-A2.1-restricted Cytotoxic T Lymphocytes Is Mediated by At Least Six Shared Peptide Epitopes" J. Immunol. 150:2955-2960 (1993)		
148.	Snoke et al., J. Immunol. (1993) 151:68	815-6821		
149.	Storkus et al. "Identification of Human Infiltrating T Lymphocytes" J. Immuno	Melanoma Peptides Recognized ol. 151:3719-3727 (1993)	d by Class I Restricted Tumor	
150.	Tangri et al., Journal of Experimental M	Medicine (2001) In Press		
151.	Threlkeld et al., J. Immunol. (1997) 15	9:1648-1657		
152.	Traversari et al. "A Nonapeptide Encoc	led by Human Gene MAGE-1 Is	s Recognized on HLA-A1 by	
EVAMINIED:		DATE CONSIDERED.		

EXAMINER:

DATE CONSIDERED:

FEB 2 2 2005 PTO/SB/08 (2-92) Sheet 8 of 8 Docket Number 399632001920 Application Number 09/189,702 Form PTO-1449 INFORMATION DISCLOSURE CITATION Applicant Alessandro SETTE, et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date November 10, 1998 Group Art Unit 1644 Mailing Date July 5, 2002 Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E" J. Exp. Med. 176:1453-1457 (1992)Tsai et al., J. Immunol. (1997) 1796-1802 153. 154. Urban et al. "Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide-Based Therapy" Cell 59:257-271 (1989) Van der Bruggen et al. "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a 155. Human Melanoma" Science 254:1643-1647 (1991) Van Der Most et al., J. Immunol. (1996) 157:5543-5554 156.

	157.	Van Der Most et al., Virology (1997) 71:5110-5114
	158.	Van Der Most et al., Virology (1998) 240:158-167
	159.	Viret et al. "Recognition of Shared Melanoma Antigen by HLA-A2 Restricted Cytolytic T Cell Clones Derived from Human Tumor-infiltrating Lymphocytes" Eur. J. Immunol. (1993)
	160.	Vitiello et al. "Development of a Lipopeptide Based Therapeutic Vaccine to Treat Chronic HBV Infection" J. Clin. Invest. 95:341-349 (1995)
	161.	Vitiello et al., J. Immunol. (1996) 157:5555-5562
	162.	Wei et al. "HLA-A2 Molecules in an Antigen-Processing Mutant Cell Contain Signal Sequencederived Peptides" Nature 356:443-446 (1992)
	163.	Wentworth et al., Eur. J. Immunol. (1996) 26:97-101
	164.	Weynants et al. "Expression of MAGE Genes by Non-Small-Cell Lung Carcinomas" Int. J. Cancer 56:826-829 (1994)
	165.	Wilson et al., J. Virol. (2001) 75:4195-4207
	166.	Wizel et al., J. Clin. Invest. (1998) 102:1062-1071
	167.	Wraith et al. "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy" Cell 59:247-255 (1989)
	168.	Wysocka et al. "Class I H-2d-Restricted Cytotoxic T Lymphocytes Recognize the Neuraminidase Glycoprotein of Influenza Virus Subtype N1" Journal of Virology 64(3):1028-1032 (1990)
	169.	Yewdell and Bennick, Annu. Rev. Immunol. (1999) 17:51-88
	170.	Yoon et al., Virus Research (1998) 54:23-29
-	171.	York and Rock, Annu. Rev. Immunol. (1996) 14:369-396
	172.	Zakut et al, "Differential Expression of MAGE-1, -2, and -3 Messenger RNA in Transformed and Normal Human Cell Lines" Cancer Res. 53:5-8 (1993)
	173.	Zhang et al., Proc. Natl. Acad. Sci. USA (1993) 90(6):2217-2221

EXAMINER:

DATE CONSIDERED: